Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Hybio Pharmaceutical Co. Ltd (Site 1)
EIR
•Hybio Pharmaceutical Co. Ltd (Site 1)•June 26, 2015

Hybio Pharmaceutical Co. Ltd (Site 1) – FDA EIR, Jun 26, 2015

Record Details

The U.S. Food and Drug Administration conducted an initial Pre-Approval and Good Manufacturing Practice (GMP) inspection of Hybio Pharmaceutical Co. Ltd in Shenzhen, China, from June 22 to June 26, 2015. This assessment, performed under CDER's compliance programs for active pharmaceutical ingredients (APIs), aimed to evaluate the company's adherence to regulatory standards for products intended for the U.S. market. The inspection covered various systems, including Quality, Facilities and Equipment, Production, Materials, Packaging and Labeling, and Laboratory Control Systems.

The FDA identified four main objectionable conditions, documented on an FDA-483 form. These included inadequate laboratory controls for in-process materials, insufficient use of protective apparel to prevent product contamination, uncontrolled air recirculation in production areas, and deficient procedures for equipment cleaning and maintenance. Additional observations noted an outdated operating system for labeling software and concerns with analytical method validation.

Hybio Pharmaceutical Co. Ltd's management acknowledged these findings, committing to implement necessary corrective actions. Some of these actions were reportedly initiated and verified during the inspection. The company was required to submit a comprehensive written response to the FDA within 15 business days. As a result of the firm's commitment to address the issues, the inspection was classified as "Voluntary Action Indicated" (VAI), indicating that regulatory action was not deemed necessary at that time.

Company
Hybio Pharmaceutical Co. Ltd (Site 1)
Inspection date
June 26, 2015
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Binh T. Nguyen (Investigator)
  • Temeka Moore (other)
  • Dennis Cantrellos Paite
  • Tony A. Wilson (investigator)
View Company Profile

ID · 76a71a07-5714-4010-baea-74791d10776b

Other documents for Hybio Pharmaceutical Co. Ltd (Site 1)
  • EIR - 2018-03-30March 30, 2018
  • 483 - 2015-06-26June 26, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hybio Pharmaceutical Co. Ltd (Site 1)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.